MX2019010931A - Metodos, composiciones, y kits para tratar y/o prevenir un efecto secundario asociado con radiacion y/o exposicion a quimioterapia. - Google Patents

Metodos, composiciones, y kits para tratar y/o prevenir un efecto secundario asociado con radiacion y/o exposicion a quimioterapia.

Info

Publication number
MX2019010931A
MX2019010931A MX2019010931A MX2019010931A MX2019010931A MX 2019010931 A MX2019010931 A MX 2019010931A MX 2019010931 A MX2019010931 A MX 2019010931A MX 2019010931 A MX2019010931 A MX 2019010931A MX 2019010931 A MX2019010931 A MX 2019010931A
Authority
MX
Mexico
Prior art keywords
kits
compositions
methods
radiation
chemotherapy
Prior art date
Application number
MX2019010931A
Other languages
English (en)
Other versions
MX394244B (es
Inventor
Batinic-Haberle Ines
ASHCRAFT Kathleen
Dewhirst Mark
D Crapo James
Original Assignee
Biomimetix Jv Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomimetix Jv Llc filed Critical Biomimetix Jv Llc
Publication of MX2019010931A publication Critical patent/MX2019010931A/es
Publication of MX394244B publication Critical patent/MX394244B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen en la presente metodos, composiciones, y kits para tratar y/o prevenir en un sujeto uno o mas efectos secundarios asociados con radiacion y/o exposicion a quimioterapia,incluyendo metodos, composiciones y kits que incluyen un agente activo a una baja dosis; en algunas modalidades, se proporcionan metodos, composiciones, y kits para tratar y/o prevenir daño al tejido en un sujeto, incluyendo metodos, composiciones y kits que incluyen un agente activo a una dosis baja.
MX2019010931A 2017-04-04 2018-04-04 Metodos, composiciones, y kits para tratar y/o prevenir un efecto secundario asociado con radiacion y/o exposicion a quimioterapia MX394244B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762481460P 2017-04-04 2017-04-04
PCT/US2018/026002 WO2018187411A1 (en) 2017-04-04 2018-04-04 Methods, compositions, and kits for treating and/or preventing a side effect associated with radiation and/or chemotherapy exposure

Publications (2)

Publication Number Publication Date
MX2019010931A true MX2019010931A (es) 2020-01-21
MX394244B MX394244B (es) 2025-03-24

Family

ID=63712315

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010931A MX394244B (es) 2017-04-04 2018-04-04 Metodos, composiciones, y kits para tratar y/o prevenir un efecto secundario asociado con radiacion y/o exposicion a quimioterapia

Country Status (10)

Country Link
US (3) US11285162B2 (es)
EP (2) EP4603096A1 (es)
JP (1) JP7333560B2 (es)
KR (2) KR20240116576A (es)
CN (1) CN110621377A (es)
CA (1) CA3052875A1 (es)
ES (1) ES3033013T3 (es)
MX (1) MX394244B (es)
PL (1) PL3606614T3 (es)
WO (1) WO2018187411A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240116576A (ko) * 2017-04-04 2024-07-29 바이오미매틱스 제이브이, 엘엘씨 방사선 요법 및/또는 화학요법 노출과 연관된 부작용의 치료 및/또는 예방을 위한 방법, 조성물, 및 키트
CN111011309A (zh) * 2020-03-03 2020-04-17 江西中医药大学 一种化疗药物致大鼠口腔溃疡模型建立方法及其应用
CN115838797B (zh) * 2022-11-22 2025-03-14 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种与放化疗引起的听力损伤相关的snp标志物及其应用
WO2025188644A1 (en) * 2024-03-04 2025-09-12 Rigel Pharmaceuticals, Inc. Treatment of cns tumors with olutasidenib and temozolomide

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448239B1 (en) 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof
EP1392328B1 (en) * 2001-01-19 2009-08-12 National Jewish Medical and Research Center Medicament for protection in radiotherapy
EP1718201B1 (en) 2004-02-09 2016-09-14 Duke University Substituted porphyrins
CN101235036A (zh) * 2007-02-02 2008-08-06 济南赛文医药技术有限公司 一类卟啉衍生物及其作为小分子抗氧化剂的应用
WO2010080881A1 (en) 2009-01-07 2010-07-15 Duke University Substituted porphyrins
WO2015034777A1 (en) 2013-09-03 2015-03-12 Biomimetix J.V., Llc Methods of treating biofilms
US10064871B2 (en) * 2014-01-22 2018-09-04 Biomimetix Jv, Llc Methods of treating skin disorders
US10080759B2 (en) 2014-01-22 2018-09-25 Duke University Methods of treating pruritus
CN110291060A (zh) * 2016-12-20 2019-09-27 杜克大学 制备取代卟啉药物化合物和组合物的方法
KR20240116576A (ko) * 2017-04-04 2024-07-29 바이오미매틱스 제이브이, 엘엘씨 방사선 요법 및/또는 화학요법 노출과 연관된 부작용의 치료 및/또는 예방을 위한 방법, 조성물, 및 키트
WO2018237249A1 (en) * 2017-06-22 2018-12-27 Biomimetix Jv, Llc Methods, compositions, and kits for treating inflammatory skin conditions
CN111417400B (zh) 2017-09-29 2022-12-02 杜克大学 氟取代的卟啉化合物、包含其的药物组合物及其制备和使用方法

Also Published As

Publication number Publication date
EP3606614A1 (en) 2020-02-12
EP3606614B1 (en) 2025-05-21
JP2020515630A (ja) 2020-05-28
US20220193090A1 (en) 2022-06-23
KR20190130654A (ko) 2019-11-22
CN110621377A (zh) 2019-12-27
KR20240116576A (ko) 2024-07-29
MX394244B (es) 2025-03-24
ES3033013T3 (en) 2025-07-29
PL3606614T3 (pl) 2025-09-15
CA3052875A1 (en) 2018-10-11
EP4603096A1 (en) 2025-08-20
JP7333560B2 (ja) 2023-08-25
EP3606614A4 (en) 2020-10-28
US20210106594A1 (en) 2021-04-15
US20250041314A1 (en) 2025-02-06
EP3606614C0 (en) 2025-05-21
US11285162B2 (en) 2022-03-29
WO2018187411A1 (en) 2018-10-11
US12171769B2 (en) 2024-12-24

Similar Documents

Publication Publication Date Title
CL2023000848A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
MX2018012486A (es) Composiciones para aplicacion topica de compuestos.
CO2017011536A2 (es) Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo
MX387788B (es) Uso de agentes activos durante tratamientos quimicos.
MX2016006025A (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
NI201200181A (es) Métodos de terapia combinada para tratar enfermedades proliferativas
BR112017011536A2 (pt) terapias de combinação
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
MX2019010931A (es) Metodos, composiciones, y kits para tratar y/o prevenir un efecto secundario asociado con radiacion y/o exposicion a quimioterapia.
GT201700167A (es) Terapias de combinación para el tratamiento de cánceres.
MX2016000271A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
CL2017000317A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d
BR112018071023A2 (pt) combinações para o tratamento de neoplasmas utilizando o direcionamento de células inativas e inibidores da mitose
BR112015023439A2 (pt) combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki
MX2019014428A (es) Resina de cromatografia esteril y uso de la misma en procesos de fabricacion.
CL2020002993A1 (es) Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica (divisional de solicitud no 1304-2019)
MX2019003722A (es) Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan.
MX379984B (es) Reducción de la sensación de picazón en la piel.
CL2015002171A1 (es) Métodos de tratamiento de la dificiencia de hierro con pirofosfato férrico soluble.
MX387658B (es) Métodos para tratar y/o prevenir queratosis actínica.
CO2017012645A2 (es) Agente antihipertensivo que comprende s-1-propenilcisteína o una sal del mismo como ingrediente activo
CO2017006983A2 (es) Una composición fungicida que comprende una n-ciclopropil- n-[bencilo sustituido]-3-(difluorometil)-5-fluoro-1- metil-1-h-pirazol-4-carboxamida o derivado de tiocarboxamida y dos compuestos fungicidas activos adicionales
CL2022001458A1 (es) Método para el tratamiento de cáncer utilizando célula ad-yuvante artificial (aavc)
MX2021003263A (es) Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer.